Web Content Viewer


Canon U.S.A. Announces Strategic Investment In Spartan Bioscience

Canon BioMedical, Inc. to help support the R&D of future diagnostic products

MELVILLE, N.Y., March 18, 2015 - Canon U.S.A., Inc., a leader in digital imaging solutions, today announced that it has made a strategic investment in Spartan Bioscience Inc., a leader in on-demand DNA testing, to help fund the research and development of new diagnostic testing products. Canon BioMedical, Inc., the recently established wholly- owned subsidiary of Canon U.S.A., Inc., plans to explore areas to work with Spartan on the development of future diagnostic products, including rapid genetic testing.

"Canon is excited to work with Spartan Bioscience Inc., on developing breakthrough technologies in the area of genetic testing," said Seymour Liebman, executive vice president, chief administrative officer and general counsel, Canon U.S.A., Inc. "Spartan's goals align with our mission to provide enhanced diagnostic testing systems that can help improve human health worldwide."

"We are excited to continue our efforts as we move into new markets for rapid genetic testing," said Paul Lem, M.D., CEO of Spartan Bioscience Inc. "Working with Canon will help accelerate our progress in the future."

Seymour Liebman, member of the Board of Directors of Canon BioMedical, Inc., will join the Board of Directors of Spartan Bioscience.

About Canon BioMedical, Inc.

Canon BioMedical, Inc. is focused on empowering the biomedical research and healthcare communities by developing, manufacturing and marketing innovative technologies and solutions. The technologies and solutions developed will help enable clinicians and scientists to improve our health and advance science. Canon BioMedical will continue to pursue innovative solutions in line with Canon's Kyosei philosophy through the use of existing and emerging Canon technology, as well as strategic partnerships.

About Canon U.S.A., Inc.

Canon U.S.A., Inc., is a leading provider of consumer, business-to-business, and industrial digital imaging solutions to the United States and to Latin America and the Caribbean (excluding Mexico) markets. With approximately $31 billion in global revenue, its parent company, Canon Inc. (NYSE:CAJ), ranks third overall in U.S. patents granted in 2014† and is one of Fortune Magazine's World's Most Admired Companies in 2015. In 2014, Canon U.S.A. has received the PCMag.com Readers' Choice Award for Service and Reliability in the digital camera and printer categories for the 11th consecutive year. Canon U.S.A. is committed to the highest level of customer satisfaction and loyalty, providing 100 percent U.S.-based consumer service and support for all of the products it distributes. Canon U.S.A. is dedicated to its Kyosei philosophy of social and environmental responsibility. In 2014, the Canon Americas Headquarters secured LEED® Gold certification, a recognition for the design, construction, operations and maintenance of high-performance green buildings. To keep apprised of the latest news from Canon U.S.A., sign up for the Company's RSS news feed by visiting www.usa.canon.com/rss and follow us on Twitter @CanonUSA. For media inquiries, please contact pr@cusa.canon.com.

About Spartan Bioscience Inc.

Spartan Bioscience Inc. is the leader in on-demand DNA testing.1 Spartan is bringing complete sample-to-result DNA testing systems to medicine. Spartan's technology fully integrates DNA collection, extraction, and analysis, with an intuitive interface that is easy to operate. For the first time, healthcare providers and their patients can get DNA results on demand. For more information, please visit our website at: http://www.spartanbio.com.


† Based on weekly patent counts issued by United States Patent and Trademark Office.

All referenced product names, and other marks, are trademarks of their respective owners.

1 Roberts JD et al. (2012). Lancet. 379:1705-11.